好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Declines in Work Productivity in Persons With Multiple Sclerosis by PDDS Score
Multiple Sclerosis
P13 - Poster Session 13 (8:00 AM-9:00 AM)
3-005
To describe differences in employment status and work productivity by Patient Determined Disease Steps (PDDS) score.

The PDDS scale measures patient-reported disability in persons with MS (pwMS). Evidence suggests that reported increases in MS symptom severity adversely impact work productivity (Glanz 2012); it is unknown how employment status varies by disability level (Bessing 2021). Examining work productivity by PDDS provides a better understanding of disease burden in pwMS. 

The sample included all participants aged 18–62 years in the US who responded to North American Research Committee on Multiple Sclerosis survey at least once in Fall 2017–Fall 2019 and reported PDDS score and employment status. If multiple surveys were available, the most recent was analyzed. Employment outcomes in the 6 months before the survey, including employment status, hours worked per week, any cutback in hours, number of missed workdays and receipt of disability benefits, were summarized overall and by PDDS score.

 

The sample included 3870 pwMS across all PDDS scores (normal, 21%; mild, 17%; moderate, 11%; gait disability, 13%; early cane, 12%; late cane, 8%; bilateral support: 8%, wheelchair/scooter, 10%; bedridden, 1%). Overall, 47% of pwMS were employed full/part-time in the prior 6 months. The proportion of pwMS who were employed declined from 81% in pwMS with a normal PDDS score and 69% with mild disability to 12% in pwMS with wheelchair/scooter and 0% in bedridden pwMS. Among all employed pwMS, 73% worked >30 hours/week, 16% cutback hours and 38% missed workdays in the prior 6 months. Receipt of disability benefits increased rapidly from 9% in pwMS with normal scores to 96% in bedridden pwMS.

PwMS with more disability were less likely to be employed and reported lower work productivity. Interventions that can address MS disability may result in slower declines in work productivity.

Authors/Disclosures
Caroline K. Geiger, PhD (Genentech Inc. - South San Francisco, CA)
PRESENTER
Dr. Geiger has received personal compensation for serving as an employee of Genentech, Inc. Dr. Geiger has stock in Moderna. Dr. Geiger has stock in Abbott Laboratories. Dr. Geiger has stock in Gilead Sciences. Dr. Geiger has stock in Amgen. Dr. Geiger has stock in Roche. Dr. Geiger has received research support from National Science Foundation.
Nicole G. Bonine, PhD (Genentech) Mrs. Bonine has received personal compensation for serving as an employee of Genentech. Mrs. Bonine has stock in Genentech.
Vanessa Di Felice, MD, MPH (Genentech) Dr. Di Felice has received personal compensation for serving as an employee of Genentech.
Amber Salter, PhD (UT Southwestern Medical Center) Dr. Salter has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gryphon Bio. Dr. Salter has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Abata Therapeutics. Dr. Salter has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sora Neuroscience. Dr. Salter has stock in Owl Therapeutics. The institution of Dr. Salter has received research support from National Multiple Sclerosis Society. The institution of Dr. Salter has received research support from Department of Defense Congressionally Directed Medical Research Program. The institution of Dr. Salter has received research support from Consortium of Multiple Sclerosis Centers.